Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model

Masashi Mizuno, Yasuhiko Ito, Natalie Hepburn, Tomohiro Mizuno, Yukihiro Noda, Yukio Yuzawa, Claire L. Harris, B. Paul Morgan, Seiichi Matsuo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Fungal peritonitis is an important complication in peritoneal dialysis patients; either continuous or recurrent peritonitis may enhance peritoneal damage. Even when the peritoneal dialysis catheter is removed in patients with fungal peritonitis, peritoneal fibrosis can progress and evolve into encapsular peritoneal sclerosis. It is unclear why fungal infections are worse than bacterial in these respects. Zymosan is a cell wall component of yeast that strongly activates the complement system. In this study, we compared the effects of zymosan and bacterial LPS on peritoneal inflammation in a rat peritoneal injury model induced by mechanical scraping. Intraperitoneal administration of zymosan, but not LPS or vehicle, caused markedly enhanced peritonitis with massive infiltration of cells and deposition of complement activation products C3b and membrane attack complex on day 5. In rats administered zymosan and sacrificed on days 18 or 36, peritoneal inflammation persisted with accumulation of ED-1-positive cells, small deposits of C3b and membrane attack complex, exudation of fibrinogen, and capillary proliferation in subperitoneal tissues. When zymosan was administered daily for 5 days after peritoneal scrape, there was even greater peritoneal inflammation with peritoneal thickening, inflammatory cell accumulation, and complement deposition. Inhibition of systemic complement by pretreatment with cobra venom factor or local inhibition by i.p. administration of the recombinant complement regulator Crry-Ig reduced peritoneal inflammation in zymosan-treated rats. Our results show that yeast components augment inflammation in the injured peritoneum by causing complement activation within the peritoneal cavity. Local anticomplement therapy may therefore protect from peritoneal damage during fungal infection of the peritoneum.

Original languageEnglish
Pages (from-to)1403-1412
Number of pages10
JournalJournal of Immunology
Volume183
Issue number2
DOIs
Publication statusPublished - 15-07-2009
Externally publishedYes

Fingerprint

Zymosan
Complement Activation
Peritonitis
Lipopolysaccharides
Inflammation
Wounds and Injuries
Peritoneal Fibrosis
Complement Membrane Attack Complex
Mycoses
Peritoneum
Peritoneal Dialysis
Yeasts
Peritoneal Cavity
Cellular Structures
Fibrinogen
Cell Wall
Catheters

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Mizuno, Masashi ; Ito, Yasuhiko ; Hepburn, Natalie ; Mizuno, Tomohiro ; Noda, Yukihiro ; Yuzawa, Yukio ; Harris, Claire L. ; Morgan, B. Paul ; Matsuo, Seiichi. / Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. In: Journal of Immunology. 2009 ; Vol. 183, No. 2. pp. 1403-1412.
@article{304937ad33574305b784bc4eb5f72c2e,
title = "Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model",
abstract = "Fungal peritonitis is an important complication in peritoneal dialysis patients; either continuous or recurrent peritonitis may enhance peritoneal damage. Even when the peritoneal dialysis catheter is removed in patients with fungal peritonitis, peritoneal fibrosis can progress and evolve into encapsular peritoneal sclerosis. It is unclear why fungal infections are worse than bacterial in these respects. Zymosan is a cell wall component of yeast that strongly activates the complement system. In this study, we compared the effects of zymosan and bacterial LPS on peritoneal inflammation in a rat peritoneal injury model induced by mechanical scraping. Intraperitoneal administration of zymosan, but not LPS or vehicle, caused markedly enhanced peritonitis with massive infiltration of cells and deposition of complement activation products C3b and membrane attack complex on day 5. In rats administered zymosan and sacrificed on days 18 or 36, peritoneal inflammation persisted with accumulation of ED-1-positive cells, small deposits of C3b and membrane attack complex, exudation of fibrinogen, and capillary proliferation in subperitoneal tissues. When zymosan was administered daily for 5 days after peritoneal scrape, there was even greater peritoneal inflammation with peritoneal thickening, inflammatory cell accumulation, and complement deposition. Inhibition of systemic complement by pretreatment with cobra venom factor or local inhibition by i.p. administration of the recombinant complement regulator Crry-Ig reduced peritoneal inflammation in zymosan-treated rats. Our results show that yeast components augment inflammation in the injured peritoneum by causing complement activation within the peritoneal cavity. Local anticomplement therapy may therefore protect from peritoneal damage during fungal infection of the peritoneum.",
author = "Masashi Mizuno and Yasuhiko Ito and Natalie Hepburn and Tomohiro Mizuno and Yukihiro Noda and Yukio Yuzawa and Harris, {Claire L.} and Morgan, {B. Paul} and Seiichi Matsuo",
year = "2009",
month = "7",
day = "15",
doi = "10.4049/jimmunol.0804245",
language = "English",
volume = "183",
pages = "1403--1412",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. / Mizuno, Masashi; Ito, Yasuhiko; Hepburn, Natalie; Mizuno, Tomohiro; Noda, Yukihiro; Yuzawa, Yukio; Harris, Claire L.; Morgan, B. Paul; Matsuo, Seiichi.

In: Journal of Immunology, Vol. 183, No. 2, 15.07.2009, p. 1403-1412.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model

AU - Mizuno, Masashi

AU - Ito, Yasuhiko

AU - Hepburn, Natalie

AU - Mizuno, Tomohiro

AU - Noda, Yukihiro

AU - Yuzawa, Yukio

AU - Harris, Claire L.

AU - Morgan, B. Paul

AU - Matsuo, Seiichi

PY - 2009/7/15

Y1 - 2009/7/15

N2 - Fungal peritonitis is an important complication in peritoneal dialysis patients; either continuous or recurrent peritonitis may enhance peritoneal damage. Even when the peritoneal dialysis catheter is removed in patients with fungal peritonitis, peritoneal fibrosis can progress and evolve into encapsular peritoneal sclerosis. It is unclear why fungal infections are worse than bacterial in these respects. Zymosan is a cell wall component of yeast that strongly activates the complement system. In this study, we compared the effects of zymosan and bacterial LPS on peritoneal inflammation in a rat peritoneal injury model induced by mechanical scraping. Intraperitoneal administration of zymosan, but not LPS or vehicle, caused markedly enhanced peritonitis with massive infiltration of cells and deposition of complement activation products C3b and membrane attack complex on day 5. In rats administered zymosan and sacrificed on days 18 or 36, peritoneal inflammation persisted with accumulation of ED-1-positive cells, small deposits of C3b and membrane attack complex, exudation of fibrinogen, and capillary proliferation in subperitoneal tissues. When zymosan was administered daily for 5 days after peritoneal scrape, there was even greater peritoneal inflammation with peritoneal thickening, inflammatory cell accumulation, and complement deposition. Inhibition of systemic complement by pretreatment with cobra venom factor or local inhibition by i.p. administration of the recombinant complement regulator Crry-Ig reduced peritoneal inflammation in zymosan-treated rats. Our results show that yeast components augment inflammation in the injured peritoneum by causing complement activation within the peritoneal cavity. Local anticomplement therapy may therefore protect from peritoneal damage during fungal infection of the peritoneum.

AB - Fungal peritonitis is an important complication in peritoneal dialysis patients; either continuous or recurrent peritonitis may enhance peritoneal damage. Even when the peritoneal dialysis catheter is removed in patients with fungal peritonitis, peritoneal fibrosis can progress and evolve into encapsular peritoneal sclerosis. It is unclear why fungal infections are worse than bacterial in these respects. Zymosan is a cell wall component of yeast that strongly activates the complement system. In this study, we compared the effects of zymosan and bacterial LPS on peritoneal inflammation in a rat peritoneal injury model induced by mechanical scraping. Intraperitoneal administration of zymosan, but not LPS or vehicle, caused markedly enhanced peritonitis with massive infiltration of cells and deposition of complement activation products C3b and membrane attack complex on day 5. In rats administered zymosan and sacrificed on days 18 or 36, peritoneal inflammation persisted with accumulation of ED-1-positive cells, small deposits of C3b and membrane attack complex, exudation of fibrinogen, and capillary proliferation in subperitoneal tissues. When zymosan was administered daily for 5 days after peritoneal scrape, there was even greater peritoneal inflammation with peritoneal thickening, inflammatory cell accumulation, and complement deposition. Inhibition of systemic complement by pretreatment with cobra venom factor or local inhibition by i.p. administration of the recombinant complement regulator Crry-Ig reduced peritoneal inflammation in zymosan-treated rats. Our results show that yeast components augment inflammation in the injured peritoneum by causing complement activation within the peritoneal cavity. Local anticomplement therapy may therefore protect from peritoneal damage during fungal infection of the peritoneum.

UR - http://www.scopus.com/inward/record.url?scp=70249096015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249096015&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0804245

DO - 10.4049/jimmunol.0804245

M3 - Article

C2 - 19553534

AN - SCOPUS:70249096015

VL - 183

SP - 1403

EP - 1412

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -